Oncology has always been a singular therapy area, covering a bewildering varieties of tumour types, conditions and clinical challenges.
Across the NHS it has special status too – its own strategy and its own formalised set of clinical networks that no other therapy area has.
At the HSJ Cancer Forum last month, I learned three important things which I thought demonstrated how the NHS could work in the future. Here’s what I think pharma should know.
Check out the rest of this feature here
